Dear editor:
We read the published study by Chu-Yu Jing et al, “HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1[1]”.
The author evaluated the prognostic value of HHLA2 in the paper, but we cannot find the univariate HR for OS and RFS in the supplementary materials. Although the results of univariate analysis between HHLA2 expression and RFS is a negative result, we believe that it is still important to provide the detailed statistical data of negative results[2]. Publishing these results will help expand the value of these results, which will be helpful for further study to understand a more accurate prognostic value of HHLA2.
1. Jing, C.-Y., et al., HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1. Journal for ImmunoTherapy of Cancer, 2019. 7(1): p. 77.
2. In praise of replication studies and null results. Nature, 2020. 578(7796): p. 489-490.
Dear editor:
We read the published study by Chu-Yu Jing et al, “HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1[1]”.
The author evaluated the prognostic value of HHLA2 in the paper, but we cannot find the univariate HR for OS and RFS in the supplementary materials. Although the results of univariate analysis between HHLA2 expression and RFS is a negative result, we believe that it is still important to provide the detailed statistical data of negative results[2]. Publishing these results will help expand the value of these results, which will be helpful for further study to understand a more accurate prognostic value of HHLA2.
1. Jing, C.-Y., et al., HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1. Journal for ImmunoTherapy of Cancer, 2019. 7(1): p. 77.
2. In praise of replication studies and null results. Nature, 2020. 578(7796): p. 489-490.